Login to Your Account



Financings Roundup

No Bones About It: $35M Add Helps Drive Thrasos' AKI Drug

By Randy Osborne
Staff Writer

Friday, October 26, 2012
The ripe market for an acute kidney injury (AKI) therapy good enough to win FDA approval drew Thrasos Therapeutics Inc. into the game, and $35 million in funding should help the company through Phase II trials with THR-184, its lead compound.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription